Sign in

    Nicholas Econom • Cantor Fitzgerald

    Nicholas Econom's questions to WAVE Life Sciences Ltd (WVE) leadership

    Nicholas Econom's questions to WAVE Life Sciences Ltd (WVE) leadership • Q1 2025

    Question

    Nicholas Econom of Cantor Fitzgerald inquired about the lung tissue distribution profile of Wave's AIMers and whether the company remains confident in a semi-annual or annual dosing strategy for its INHBE program, given a competitor is targeting quarterly dosing.

    Answer

    Chief Scientific Officer Dr. Erik Ingelsson explained that lung distribution is achieved through PN chemistry optimization, not a conjugate. President and CEO Dr. Paul Bolno expressed high confidence in their less frequent dosing strategy for the INHBE program. He cited preclinical data published in NAR showing their siRNA format has 30-fold superior AGO2 loading, which translates to greater potency and durability compared to competitor platforms.

    Ask Fintool Equity Research AI

    Nicholas Econom's questions to Apellis Pharmaceuticals Inc (APLS) leadership

    Nicholas Econom's questions to Apellis Pharmaceuticals Inc (APLS) leadership • Q3 2024

    Question

    Nicholas Econom, on behalf of Steve Seedhouse at Raymond James, asked about potential future renal indications for pegcetacoplan and the timeline for announcing further clinical development plans in nephrology.

    Answer

    CEO Dr. Cedric Francois provided a direct response, stating that while they are not ready to announce specific plans yet, they are actively working on it and expect to provide more clarity on their nephrology pipeline expansion in the coming months.

    Ask Fintool Equity Research AI